Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
Clinical trial NCT03440736 · COMPLETED
Trial details
- NCT number
- NCT03440736
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-28
- Primary completion
- 2021-11-30
- Enrollment
- 781
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.